Search results for " lymphoma"

showing 10 items of 448 documents

A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection

2012

Human cytomegalovirusPathologymedicine.medical_specialtyType B Lymphomatoid PapulosisUlcerative proctitisbusiness.industryRare casemedicineDermatologymedicine.diseasebusinessInternational Journal of Dermatology
researchProduct

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.

2012

We performed an immunogenetic analysis of 345 IGHV-IGHD-IGHJ rearrangements from 337 cases with primary splenic small B-cell lymphomas of marginal-zone origin. Three immunoglobulin (IG) heavy variable (IGHV) genes accounted for 45.8% of the cases (IGHV1-2, 24.9%; IGHV4-34, 12.8%; IGHV3-23, 8.1%). Particularly for the IGHV1-2 gene, strong biases were evident regarding utilization of different alleles, with 79/86 rearrangements (92%) using allele *04. Among cases more stringently classified as splenic marginal-zone lymphoma (SMZL) thanks to the availability of splenic histopathological specimens, the frequency of IGHV1-2*04 peaked at 31%. The IGHV1-2*04 rearrangements carried significantly lo…

Immunoglobulin geneModels MolecularCancer ResearchGenes Immunoglobulin Heavy ChainGene Rearrangement B-Lymphocyte Heavy ChainImmunoglobulin Variable RegionSomatic hypermutationSplenic NeoplasmBiologyCohort StudiesantigenmedicineHumansSplenic marginal zone lymphomaAlleleGeneticsSplenic Neoplasmssplenic marginal-zone lymphomaHematologyGene rearrangementLymphoma B-Cell Marginal Zonemedicine.diseasePrognosisComplementarity Determining Regionssomatic hypermutationimmunoglobulin geneOncologyMutationIGHDsplenic marginal-zone lymphoma; immunoglobulin gene; somatic hypermutation; CDR3; antigenCDR3IGHV@Leukemia
researchProduct

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

2011

Abstract We reported that the clinical efficacy of dendritic cell–based vaccination is strongly associated with immunologic responses in relapsed B-cell non-Hodgkin lymphoma (B-NHL) patients. We have now investigated whether postvaccination antibodies from responders recognize novel shared NHL-restricted antigens. Immunohistochemistry and flow cytometry showed that they cross-react with allogeneic B-NHLs at significantly higher levels than their matched prevaccination samples or nonresponders' antibodies. Western blot analysis of DOHH-2 lymphoma proteome revealed a sharp band migrating at approximately 100 to 110 kDa only with postvaccine repertoires from responders. Mass spectrometry ident…

ImmunologyMice SCIDBiochemistryAntibodiesFlow cytometryAntigen-Antibody ReactionsCohort StudiesHSP105MiceAntigenhemic and lymphatic diseasesCell Line TumormedicineAnimalsHumansSerologic TestsHSP110 Heat-Shock Proteinsmedicine.diagnostic_testbiologybusiness.industryLymphoma Non-HodgkinHSP105; non-Hodgkin lymphoma.Cell BiologyHematologyCell cyclemedicine.diseaseImmunohistochemistryLymphomaGranzyme BGene Expression Regulation Neoplasticnon-Hodgkin lymphoma.Spectrometry Mass Matrix-Assisted Laser Desorption-IonizationImmunologybiology.proteinImmunohistochemistryAntibodybusinessDiffuse large B-cell lymphoma
researchProduct

In situ transcriptional profile of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched Diffuse Large B-cell Lymphomas

2021

AbstractThe germinal center (GC) reaction results in the selection of B-cells acquiring effector Ig secreting ability by progressing towards plasmablastic differentiation. This transition is associated with exclusion from the GC microenvironment. The aberrant expansion of plasmablastic elements within the GC fringes configures an atypical condition, the biological characteristics of which have not been defined yet. We investigated the in situ immunophenotypical and transcriptional characteristics of a non-clonal germinotropic expansion of plasmablastic elements (GEx) occurring in the tonsil of a young patient. Compared to neighboring GC and peri-follicular regions, the GEx showed a distinct…

In situTransition (genetics)Effectormedicine.medical_treatmentGerminal centerBiologymedicine.diseaseLymphomamedicine.anatomical_structureCytokineTonsilCancer researchmedicineDiffuse large B-cell lymphoma
researchProduct

O142: Treatment of HCV-associated cryoglobulinemia and B-cell lymphoma

2013

Infectious DiseasesHepatologybusiness.industryVirologyCancer researchMedicinebusinessB-cell lymphomamedicine.diseaseCryoglobulinemiaJournal of Viral Hepatitis
researchProduct

The Role of Inflammation in Lymphoma

2014

Human lymphomas usually develop in specialized tissue microenvironments characterized by different populations of accessory stromal and lymphoid cells that interact with malignant cells. A clinical role of the tumor microenvironment has recently emerged, bringing new knowledge and suggesting new ideas and targets for treatment. This chapter analyzes the microenvironment in human lymphomas highlighting the role of inflammation in their pathogenesis. Microenvironmental specificity is detailed according to different models including classic Hodgkin lymphoma (HL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma, unspecified and angioimmunoblastic T-ce…

InflammationPathologymedicine.medical_specialtyTumor microenvironmentStromal cellLymphomatoid granulomatosisFollicular lymphomalymphomaInflammationBiologymedicine.diseaseBCL10Lymphomaimmune system diseaseshemic and lymphatic diseasesmedicinemedicine.symptomBrentuximab vedotinmedicine.drug
researchProduct

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or…

2008

Abstract Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized CD22 antibody, conjugated to calicheamicin, a potent cytotoxic antitumor agent. Inotuzumab ozogamicin targets B-cell malignancies since they often express CD22. In a previously reported phase 1 dose-escalation trial in patients with CD22-positive B-cell non-Hodgkin’s lymphoma (NHL), the maximum tolerated dose (MTD) was determined to be 1.8 mg/m2 every 4 weeks. Responses were seen in patients with both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). This ongoing study consisted of a limited dose escalation (DE) portion to confirm the MTD of inotuzumab ozogamicin whe…

Inotuzumab ozogamicinmedicine.medical_specialtybusiness.industryImmunologyFollicular lymphomaCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryGastroenterologySurgeryTransplantationchemistry.chemical_compoundchemistryhemic and lymphatic diseasesInternal medicineCalicheamicinmedicineRituximabbusinessDiffuse large B-cell lymphomaSurvival ratemedicine.drugBlood
researchProduct

Growth, interleukin-2 production, and responsiveness to IL-2 in T4- positive T Lymphocyte populations from malignant cutaneous T cell lymphoma (Sezar…

1984

Abstract Functional analysis and surface phenotyping using monoclonal antibodies have revealed that malignant T lymphocyte populations in the peripheral blood of patients with Sezary's syndrome resemble the T helper cell populations from normal individuals. In this article we have studied the effects of the immunosuppressive drug cyclosporine A (CsA) on growth, interleukin-2 (IL-2) production, and the induction of IL-2 responsiveness of peripheral blood monocytes (PBMs) from five patients with Sezary's syndrome in vitro, using the lectin phytohemagglutinin (PHA) and the phorbol ester phorbol myristate acetate (PMA) as stimuli. The following results were obtained: PHA-induced cell proliferat…

Interleukin 2medicine.medical_specialtyT cellImmunologyCyclosporinsBiologyLymphocyte ActivationBiochemistryCyclosporin aInternal medicinemedicineHumansSezary SyndromePhytohemagglutininsReceptorCell growthCutaneous T-cell lymphomaT-Lymphocytes Helper-InducerCell BiologyHematologyT helper cellT lymphocytemedicine.diseasePhenotypemedicine.anatomical_structureEndocrinologyInterleukin-2Tetradecanoylphorbol Acetatemedicine.drugBlood
researchProduct

Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

2014

Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma subtype and is clinically aggressive. To identify genetic susceptibility loci for DLBCL, we conducted a meta-analysis of 3 new genome-wide association studies (GWAS) and 1 previous scan, totaling 3,857 cases and 7,666 controls of European ancestry, with additional genotyping of 9 promising SNPs in 1,359 cases and 4,557 controls. In our multi-stage analysis, five independent SNPs in four loci achieved genome-wide significance marked by rs116446171 at 6p25.3 (EXOC2; P = 2.33 × 10 '21), rs2523607 at 6p21.33 (HLA-B; P = 2.40 × 10 '10), rs79480871 at 2p23.3 (NCOA1; P = 4.23 × 10 '8) and two independent SNPs, rs13255292 and rs47336…

LimfomesGenotypeChronic lymphocytic leukemiaCèl·lules BQuantitative Trait LociPopulationFollicular lymphomaGenome-wide association studySingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideArticleWhite PeopleGeneticsGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseeducationGenetic associationGeneticsLikelihood Functionseducation.field_of_studyB cellsChromosome MappingComputational Biologymedicine.diseaseGenetic Locilarge B cell lymphoma (DLBCL)LymphomasLymphoma Large B-Cell DiffuseDiffuse large B-cell lymphomaGenome-Wide Association Study
researchProduct

Diagnóstico de Metástasis Ováricas de un linfoma B diseminado mediante ecografía 3D

2018

RESUMEN La participación del aparato genitourinario en el contexto de la enfermedad hematológica maligna es bien conocida. No obstante, la afectación ovárica por linfomas es inusual, ya sea de novo o como manifestación tardía de linfoma diseminado. El objetivo de esta comunicación es exponer la aportación diagnóstica de la ecografía tridimensional (3D) en la detección de metástasis ováricas, cuando todavía algunas de las pruebas de imagen estándar como la tomografía computarizada (TAC) son normales. En este caso presentamos una paciente con linfoma B difuso de células grandes mediastínico de crecimiento rápido y diseminación precoz a aparato gastrointestinal y genitourinario. ABSTRACT Genit…

Linfoma B difuso de células grandesmétodos diagnósticosovarian metastasesnew modes of ultrasounddiffuse large B-cell lymphomametástasis ovaricasdiagnostic methodsnuevos modos ecográficoschemotherapyquimioterapia
researchProduct